Evaluation of the Binding of Radiolabeled Rituximab to CD20-Positive Lymphoma Cells: An In Vitro Feasibility Study Concerning Low-Dose-Rate Radioimmunotherapy with the alpha -Emitter super(227)Th

• Published in: Cancer biotherapy & radiopharmaceuticals Vol. 22; no. 4; pp. 469 - 479
• Main Authors: Melhus, K B, Larsen, R H, Stokke, T, Kaalhus, O, Selbo, P K, Dahle, J
• Format: Journal Article
• Language: English
• Published: 01.08.2007

Radioimmunotherapy (RIT) with the alpha-emitter super(227)Th is currently under evaluation. super(227)Th is conjugated to the chimeric anti-CD20 monoclonal antibody rituximab, using the chelator p-isothiocyanato-benzyl-DOTA. In this study, the binding of super(227)Th-DOTA-p-benzyl-rituximab to three...